TG Therapeutics, Inc.
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), anā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$29.21
Price-0.07%
-$0.02
1Y
Price
Market Cap
$4.637b
Mid
Price/Earnings 3y Avg5y Avg
10.6x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+20.2%
EBITDA Margin+241.7%
Net Profit Margin-14.4%
Free Cash Flow Margin+20.2%
EBITDA Margin+241.7%
Net Profit Margin-14.4%
Free Cash Flow MarginRevenue
$531.898m
+61.7%
1y CAGR+2797.5%
3y CAGR+2083.5%
5y CAGREarnings
$447.473m
+1813.7%
1y CAGR+668.0%
3y CAGR+509.9%
5y CAGREPS
$2.78
+1753.3%
1y CAGR+642.1%
3y CAGR+492.7%
5y CAGRBook Value
$607.218m
$1.025b
Assets$417.806m
Liabilities$253.716m
DebtDebt to Assets
24.8%
2.2x
Debt to EBITDAFree Cash Flow
-$70.241m
-73.2%
1y CAGR-6.7%
3y CAGR+5.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company